Search

Your search keyword '"Ana, Blasco"' showing total 16 results

Search Constraints

Start Over You searched for: Author "Ana, Blasco" Remove constraint Author: "Ana, Blasco" Journal journal of thoracic oncology Remove constraint Journal: journal of thoracic oncology
16 results on '"Ana, Blasco"'

Search Results

1. OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases

2. P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing

3. MA04.03 Lung Tumorspheres Characterization Reveals Cancer Stem-Like Cells Potential Targets and Prognostic Markers in Non-Small Cell Lung Cancer

4. P1.01-111 ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases

5. P3.02c-084 Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients

6. P1.05-014 Stemness Gene Expression Profile of Tumorspheres from Non-Small Cell Lung Cancer

7. MA 07.03 Incidence, Predictors and Prognostic Significance of Thromboembolic Events in Patients with Advanced Alk-Rearranged NSCLCs

8. P3.02c-084 Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients

9. P1.05-013 Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non-Small Cell Lung Cancer

10. P2-094: Progostic impact of Epidermal Growth Factor Receptor (EGFR) concentration in plasma in advanced non-small cell lung cancer (NSCLC) patients

11. P2-097: Determination of nerve growth factor (NGF) levels in plasma in patients with advanced non-small cell lung cancer patients (NSCLC). Its correlation with clinical outcome

12. P1-222: Activity and feasibility of biweekly carboplatin (Cb) plus Gemcitabine (G) as first line treatment in small cell lung cancer (SCLC) with extensive disease (ED)

13. P2-087: Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p)

14. P2-242: First-line treatment with vinorelbine (VRL) plus cisplatin (CDDP) for patients with advanced non-small-cell lung cancer (NSCLC): Molecular correlates

15. P2-096: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in blood in advanced non-small cell lung cancer (NSCLC) patients: Analysis of therir prognostic value

16. P2-093: The quantification of the catalytic subunit of telomerase in plasma is a prognostic factor in advanced non-small cell lung cancer (NSCLC) patients

Catalog

Books, media, physical & digital resources